Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
URL: https://web.expasy.org/cellosaurus/CVCL_F865
Proper Citation: RRID:CVCL_F865
Description: Cell line OS2 [Human osteosarcoma] is a Cancer cell line with a species of origin Homo sapiens (Human)
Sex: Female
Disease: Osteosarcoma
Defining Citation: PMID:19746444
Comments: Population: Chinese; Indonesia.
Category: Cancer cell line
Expand AllWe found {{ ctrl2.mentions.all_count }} mentions in open access literature.
We have not found any literature mentions for this resource.
We are searching literature mentions for this resource.
Most recent articles:
{{ mention._source.dc.creators[0].familyName }} {{ mention._source.dc.creators[0].initials }}, et al. ({{ mention._source.dc.publicationYear }}) {{ mention._source.dc.title }} {{ mention._source.dc.publishers[0].name }}, {{ mention._source.dc.publishers[0].volume }}({{ mention._source.dc.publishers[0].issue }}), {{ mention._source.dc.publishers[0].pagination }}. (PMID:{{ mention._id.replace('PMID:', '') }})
A list of researchers who have used the resource and an author search tool
A list of researchers who have used the resource and an author search tool. This is available for resources that have literature mentions.
No rating or validation information has been found for OS2 [Human osteosarcoma].
No alerts have been found for OS2 [Human osteosarcoma].
Source: Cellosaurus
dkNET can assist you in preparing authentication plans for cell lines to comply with the NIH Submission Policy. The information can be used while planning your experiments or submitting grant applications. The authentication plan for the cell lines is based on the International Cell Line Authentication Committee (ICLAC)'s "Cell Line Checklist for Manuscripts and Grant Applications" and the example "Authentication of of Key Biological and/or Chemical Resources "(Bandrowski A). For best practices for authenticating cell lines, check our Authentication Reports services.